It was the first time that New Jersey has brought legal action against a company based in the state as it struggles to contain a spiraling opioid addiction crisis.
New Jersey officials, taking on one of the state’s core industries, filed a lawsuit Tuesday against a subsidiary of Johnson & Johnson that manufactures opioids, accusing the pharmaceutical company of misleading patients about the addictive dangers posed by its drugs.
It was the first time that New Jersey has brought legal action against a company based in the state as it struggles to contain a spiraling opioid addiction crisis. And it comes at a time when state attorneys general across the country have intensified their efforts to hold pharmaceutical companies accountable for the epidemics of abuse.
Gurbir Grewal, the New Jersey attorney general, said the subsidiary, Janssen Pharmaceuticals, minimized the risks of opioid addiction in its marketing messages, targeted older people and other patients with little knowledge of opioids and mounted a campaign to “embed its deceptions about the viability of long-term opioid use in the minds of doctors and patients.”
“It is particularly disturbing that so much of this misconduct took place in our own backyard,” Grewal added in a statement. “New Jersey’s pharmaceutical industry is the envy of the world, with a long history of developing vital, lifesaving drugs. But we cannot turn a blind eye when a New Jersey company violates the law and threatens the lives of our residents.”
In the absence of any significant federal action to stem the opioid epidemic, states have led the charge to grapple with a health crisis that has yet to be contained. In 2017, there were more than 72,000 overdose deaths in the country from opioids, a 10 percent rise from the previous year.
More than 40 state attorneys general have joined New York state in a multiyear, wide-ranging investigation of manufacturers and distributors of opioids. Eleven states, including New Jersey, have filed separate lawsuits against Purdue Pharma, the manufacturer of OxyContin, a popular opioid painkiller.
“It became a state issue because there wasn’t a lot of movement on the federal level,” said Lewis S. Nelson, the chairman of the Department of Emergency Medicine at Rutgers University. “To this date, the federal government hasn’t been very effective at regulating the practices of these pharmaceutical companies.”
In addition to the human toll, the opioid crisis has also imposed a significant financial burden that has been largely shouldered by states, Lewis said, including paying for hospital bills, drug courts and emergency response.
In New Jersey, the state also pays for opioids through public employee health plans, according to the lawsuit.
While there have been some positive trends in the opioid epidemics at the national level, including a drop in the number of overdose deaths in parts of New England, New Jersey’s death rate has risen steadily. Nearly 2,700 overdose deaths have been confirmed in the first 10 months of this year, according to data collected by the state attorney general’s office. In 2017, preliminary data show that there were 2,750 overdose-related deaths.
The opioid crisis in New Jersey became the main focus of Gov. Chris Christie’s final year in office and he used his national platform as a presidential candidate to repeatedly call for reforms on treating opioid addiction and prosecuting drug abusers. President Donald Trump also named Christie as chairman of his commission on the opioid crisis. Besides suing Purdue Pharma, the Christie administration also sued Insys Therapeutics, an Arizona-based opioid manufacturer.